FDA Registration for Cosmetics: What Companies Must Know Under MoCRA

Home
MoCRA Compliance

The expression FDA registration for cosmetics is widely used by companies seeking to market cosmetic products in the United States. However, the term is often misunderstood. Unlike medicines or certain medical devices, cosmetic products do not require FDA pre-market approval before being sold in the U.S.

Instead, the concept of FDA registration for cosmetics generally refers to specific regulatory obligations introduced or reinforced under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), the most significant reform of U.S. cosmetic regulation in decades.

Under MoCRA, cosmetic companies must comply with several new regulatory requirements designed to strengthen oversight of cosmetic products marketed in the United States. The most notable obligations include FDA Cosmetic Facility Registration, FDA Cosmetic Product Listing, enhanced safety substantiation responsibilities, and mandatory serious adverse event reporting.

Understanding what FDA registration for cosmetics actually means is therefore essential for manufacturers, brand owners, and international companies exporting cosmetics to the U.S. market.

Is FDA Registration Required for Cosmetics

A common misconception is that cosmetic products must be approved or registered by the U.S. Food and Drug Administration before they can be sold. In reality, the FDA does not approve cosmetic products before they enter the market.

Under the Federal Food, Drug and Cosmetic Act (FD&C Act), cosmetic manufacturers are responsible for ensuring that their products are safe and properly labeled before marketing them in the United States.

However, the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) introduced mandatory regulatory obligations that significantly increased FDA oversight of cosmetic companies. These obligations are often collectively described as FDA registration for cosmetics, although they do not constitute product approval.

The main regulatory mechanisms associated with this concept are FDA Cosmetic Facility Registration and FDA Cosmetic Product Listing.

What “FDA Registration for Cosmetics” Actually Means

In regulatory practice, the term FDA registration for cosmetics generally refers to two core obligations that cosmetic companies must fulfill under MoCRA.

These obligations allow the FDA to obtain better visibility over cosmetic manufacturing facilities and the cosmetic products being marketed in the United States.

FDA Cosmetic Facility Registration

Under MoCRA, cosmetic manufacturing and processing facilities must register with the FDA.

A cosmetic facility is generally defined as an establishment that manufactures or processes cosmetic products distributed in the United States. Activities that typically trigger registration obligations include formulation, manufacturing, compounding, or processing of cosmetic products.

Certain facilities may be exempt from registration, such as small businesses that meet specific revenue thresholds, although important exceptions apply for companies manufacturing certain categories of products.

Registered facilities must provide the FDA with key information including:

Facility name and address
Contact details
Brand names of cosmetic products manufactured or processed at the facility
The designated US Agent for foreign facilities

Facility registrations must be renewed every two years. This allows the FDA to maintain an updated database of cosmetic manufacturing establishments supplying the U.S. market.

FDA Cosmetic Product Listing

In addition to facility registration, MoCRA requires cosmetic product listing.

The responsible person, typically the brand owner whose name appears on the product label, must submit information about each cosmetic product marketed in the United States.

The FDA Cosmetic Product Listing includes information such as:

Product name
Product category
Facility where the product is manufactured or processed
List of ingredients

Product listings must be submitted to the FDA and updated when significant changes occur, such as formulation updates or discontinuation of a product.

While facility registration identifies where cosmetics are manufactured or processed, product listing allows the FDA to track which cosmetic products are present on the U.S. market.

Who Must Comply with FDA Registration for Cosmetics

Several types of companies may be subject to the regulatory obligations commonly described as FDA registration for cosmetics.

These include cosmetic manufacturers and processors operating in the United States, contract manufacturers producing products for brands, brand owners acting as the responsible person for cosmetic products, companies importing cosmetic products into the United States, and distributors involved in placing cosmetic products on the U.S. market.

Although responsibilities may differ depending on the role of each operator, companies involved in the manufacture or marketing of cosmetic products must ensure that the applicable facility registration and product listing requirements are fulfilled.

FDA Registration Requirements for Foreign Cosmetic Companies

Foreign cosmetic manufacturers exporting products to the United States must also comply with the obligations introduced by MoCRA.

If a cosmetic product is manufactured or processed outside the United States and distributed in the U.S. market, the foreign manufacturing facility must be registered with the FDA.

In addition, the cosmetic product itself must be listed with the FDA by the responsible person.

Foreign companies must therefore ensure that their regulatory compliance framework covers both facility registration and product listing requirements.

Requirement to Designate a US Agent

One important requirement for foreign cosmetic facilities is the obligation to designate a US Agent.

The US Agent acts as the official contact point between the FDA and the foreign cosmetic facility. The FDA may communicate with the US Agent regarding regulatory questions, inspections, or compliance matters.

The US Agent must be located in the United States and must be authorized by the foreign facility to receive communications from the FDA.

Designating a reliable US Agent is therefore a key component of regulatory compliance for non-US cosmetic manufacturers supplying the U.S. market.

Key Compliance Obligations Under MoCRA

Beyond facility registration and product listing, MoCRA introduced several additional compliance obligations that cosmetic companies must respect.

Cosmetic companies must ensure that adequate safety substantiation exists for each cosmetic product before it is marketed. This means companies must possess reliable scientific evidence demonstrating that the product is safe under its intended conditions of use.

MoCRA also introduced mandatory serious adverse event reporting. Responsible persons must report serious adverse events associated with cosmetic products to the FDA and maintain records of adverse events received.

In addition, companies must maintain appropriate records and documentation demonstrating compliance with regulatory obligations.

These requirements significantly strengthen the regulatory framework governing cosmetic products in the United States.

Common Mistakes Companies Make About FDA Registration for Cosmetics

Many companies misunderstand what FDA registration for cosmetics actually involves.

One of the most common mistakes is assuming that cosmetic products must be approved by the FDA before they can be marketed. In reality, the FDA does not grant pre-market approval for cosmetic products.

Another common misunderstanding is confusing facility registration with product listing. These are two distinct regulatory obligations under MoCRA.

Companies may also incorrectly assume that only U.S. manufacturers must comply with these requirements. In practice, foreign cosmetic manufacturers exporting to the United States are also subject to facility registration obligations.

Finally, some companies underestimate the importance of safety substantiation and regulatory documentation, which remain fundamental responsibilities under U.S. cosmetic law.

How Cosmetic Companies Can Ensure FDA Compliance

To ensure compliance with U.S. cosmetic regulation, companies should implement a structured regulatory approach.

This typically includes identifying whether their facilities must be registered with the FDA, submitting accurate FDA Cosmetic Facility Registration, ensuring that all cosmetic products marketed in the United States are properly listed with the FDA, and verifying that each product has adequate safety substantiation.

Companies should also establish internal procedures for serious adverse event reporting, maintain detailed regulatory records, and ensure that labeling complies with applicable FDA requirements.

For foreign companies exporting cosmetics to the United States, appointing a qualified US Agent is an essential step in maintaining regulatory compliance.

Conclusion

The term FDA registration for cosmetics is widely used but often misunderstood. In the United States, cosmetic products do not require FDA approval before they are marketed.

Instead, the concept generally refers to regulatory obligations introduced or strengthened by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).

These obligations primarily include FDA Cosmetic Facility Registration, FDA Cosmetic Product Listing, designation of a US Agent for foreign facilities, and compliance with broader regulatory requirements such as safety substantiation and adverse event reporting.

For companies involved in manufacturing or marketing cosmetics in the United States, understanding these requirements is essential to ensure full regulatory compliance and to operate successfully in the U.S. cosmetic market.

Author

Biorius

First Class specialists in cosmetic regulations in Europe, United Kingdom, United States, Canada and in more than 60 countries

Related Posts

ECHA proposal to ban octocrylene in cosmetic products

1 October 2025

Publication of the 22nd Adaptation to Technical Progress: Updates to the CLP Regulation (EU 1272/2008)

29 July 2025